Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology firm specializing in developing innovative treatments for fibro-inflammatory diseases with significant unmet medical needs. The company is set to participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, where CEO Dr. Adi Mor and the senior management team will present and engage in one-on-one investor meetings. The presentation will be available via a live webcast, accessible through the Chemomab website for 90 days post-event.

Chemomab has pioneered the development of nebokitug, a first-in-class dual activity monoclonal antibody designed to neutralize the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. Nebokitug has showcased promising results across five clinical trials, demonstrating a favorable safety profile and the potential for treating various severe fibro-inflammatory conditions. Notably, positive outcomes from the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) have paved the way for the design of a Phase 3 registration trial with the FDA.

The significance of Chemomab’s work is underscored by the regulatory recognitions it has received, including Orphan Drug and Fast Track designations from the FDA and EMA for nebokitug in both PSC and systemic sclerosis. These designations reflect the medication’s therapeutic potential and address a clear gap in treatment options for patients with these challenging diseases.

As Chemomab continues to progress with its clinical trials and engages with the investment community, its cutting-edge research aims to make a substantial impact on the landscape of fibro-inflammatory disease treatment. For further information, Chemomab maintains an updated investor relations section on its website.

As Chemomab Therapeutics (NASDAQ: CMMB) prepares for its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, investors should consider the company’s promising position within the biotechnology sector. Chemomab specializes in developing therapeutics for fibro-inflammatory diseases, a space characterized by high unmet needs and significant market opportunities.

At the heart of Chemomab’s pipeline is nebokitug, a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, known for its role in fibrosis and inflammation. Recent clinical trials, particularly the Phase 2 SPRING trial for primary sclerosing cholangitis (PSC), have yielded positive results. The alignment with the FDA on a Phase 3 registration trial signals robust internal confidence and regulatory support, which are vital for advancing toward commercialization.

Investors should be aware that nebokitug's Orphan Drug and Fast Track designations enhance Chemomab’s prospects, facilitating a smoother path through clinical development while also offering potential market exclusivity. This strategic positioning not only reduces risks typically associated with biotech investments but also hints at the potential for significant upside once commercialization occurs.

Moreover, the virtual format of the conference allows for broader investor engagement, providing an opportunity for CEO Dr. Adi Mor to articulate Chemomab’s strategic direction and respond to investor queries directly. Assessing the market landscape, Chemomab’s focus on severe and life-threatening conditions places it in a favorable niche, backed by positive clinical data.

In conclusion, as Chemomab continues to progress its clinical trials and expand its portfolio, the upcoming presentation at Oppenheimer represents a pivotal moment for investor engagement. Stakeholders should closely monitor developments within the company, particularly any announcements related to clinical progress on nebokitug, as these could significantly influence share performance and market perception.